EUVIMEDEUVIMED entdecken
Fallbericht

Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab

Youichi Ogawa iD, Eri Maejima, Takuya Takeichi iD, Takashi Okamoto iD, Hiroshi Mitsui iD, Shinji Shimada, Masashi Akiyama iD, Tatsuyoshi Kawamura

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17464 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Youichi Ogawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. Hauptthemen laut MEDLINE: Psoriasis, Peroxidase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Generalized pustular psoriasis (GPP) is a recurrent and sometimes life‐threatening sterile pustular disease. Because interleukin (IL)‐36 is the central cytokine in disease formation, spesolimab, which interferes with IL‐36 receptor signaling, is highly effective. Here, we report a patient with GPP with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab. Although spesolimab showed excellent clinical efficacy in resolving pre‐existing pustules and erythema, it did not suppress the emergence of new pustules and erythema, which did not decrease the peripheral blood neutrophil count, therefore bimekizumab, an anti‐IL‐17A/IL‐17F antibody, was administered after the second spesolimab infusion, which resolved the pustules and erythema. We discuss the possible reasons for the resistance mechanism to spesolimab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisPeroxidaseHumansHeterozygoteMaleDrug ResistanceFemaleInterleukin-1Antibodies, Monoclonal, HumanizedMiddle AgedSkinInterleukins

Stichwörter der Autor:innen

generalized pustular psoriasismyeloperoxidaseneutrophilsspesolimab

Substanzen

PeroxidaseMPO protein, humanIL36RN protein, humanInterleukin-1Antibodies, Monoclonal, HumanizedInterleukins

Autor:innen und Institutionen

  • Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
  • Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Youichi Ogawa, Takuya Takeichi, Takashi Okamoto, Hiroshi Mitsui, Masashi Akiyama

Zitieren

APA

Ogawa, Y., Maejima, E., Takeichi, T., Okamoto, T., Mitsui, H., Shimada, S., Akiyama, M., & Kawamura, T. (2025). Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17464

Vancouver

Ogawa Y, Maejima E, Takeichi T, Okamoto T, Mitsui H, Shimada S, et al. Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17464

BibTeX
@article{Ogawa2025,
  author = {Ogawa, Youichi and Maejima, Eri and Takeichi, Takuya and Okamoto, Takashi and Mitsui, Hiroshi and Shimada, Shinji and Akiyama, Masashi and Kawamura, Tatsuyoshi},
  title = {Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17464}
}
Kostenlos starten →